Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESOLUTE: Benralizumab for COPD with frequent exacerbations and eosinophilia
jRCT2080224950Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Benralizumab 100 mg with Placebo (2 arms). Started Nov 2019; status: completed.
02
Drugs
benralizumab
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on jRCT2080224950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224950.